Stefan Glombitza has more than twenty years of extensive experience in the pharmaceutical industry and has distinctive expertise in the generics sector. After studying pharmacy at the University of Regensburg and subsequently gaining his PhD, he began his professional career in 1995 as Medical Affairs Manager at Hexal AG. After two years as head of the medical department, he established a project management system in the development area and ultimately was appointed to the management board of Hexal Pharmaforschung as head of project management.
With the takeover by Novartis in 2005, Dr. Glombitza’s remit expanded to cover leadership of global project and portfolio management within Sandoz’s generics division. After several years in this role he switched to the German business organization to set up the new cross-functional unit Pharmaceutical Affairs. He managed this business unit for four years until 2013, when he became head of the global development center at the austrian Sandoz facilities in Kundl and Schaftenau.
Since 2016, Dr. Glombitza directed the operational development activities at Formycon as Chief Operating Officer (COO) before being appointed Chief Executive Officer (CEO) with effect from July 01, 2022. In his role as CEO, he will shape Formycon’s strategic direction in an increasingly commercial phase of its corporate development and, together with his team of experts, drive forward with a continuously expanding portfolio of products and development projects.
Held leading management positions at Hexal and Sandoz International
More than 20 years of extensive experience in pharmaceutical industry
Outstanding expertise in Product Development, Business Development and Commercial Affairs
Former Managing Director of Bioeq GmbH
Dr. Andreas Seidl
Dr. Andreas Seidl has more than 20 years of experience in the pharmaceutical industry and biotechnology. He studied chemistry with a focus on biochemistry followed by a PhD in the field of protein analytics at the University of Konstanz. He started his professional career outside the university in 2002 at Hexal Biotech GmbH, a subsidiary of Hexal AG, where he pioneered strategies for the development and approval of biosimilars. Among other things, he was able to make decisive contributions to the development of the first complex biosimilar, Epoetin alfa Hexal/Binocrit.
From 2002 to 2010, as Head of Analytics and Quality Control, he was responsible for analytical pharmaceutical development and quality control of the first biosimilars. After the integration of Hexal AG into the Novartis Group, he managed several analytical development departments at the Oberhaching site from 2010 to 2015 and was appointed site manager there. In this role, he was also responsible for a GLP/GCLP-certified testing laboratory for preclinical and clinical analytics. From 2015 to 2019, he was assigned responsibility for several bioanalytical groups in Germany, Austria and Switzerland within the Novartis global development organization, supporting the successful development and approval of a total of eight biosimilars but also innovative biologics during this time.
From 2019 to mid-2022, Dr. Andreas Seidl served as COO on the board of Leukocare AG, an innovative biotech company in Martinsried near Munich, Germany, providing formulation and finished product development for all types of biologics (proteins, antibodies, viral vectors, vaccines, biofunctionalized medical devices) for the pharmaceutical and biotech industry. As CSO of Formycon AG since July 2022, Dr. Andreas Seidl is in charge of the scientific strategy and is responsible for Scientific Affairs as well as preclinical and clinical development on the Executive Board.
Enno Spillner has more than 23 years of experience in the biotechnology industry. In his latest position he has been serving from 2016 to 2023 as CFO and member of the Management Board of Evotec SE, which is listed on MDAX, TecDAX as well as NASDAQ. In his role as CFO he was responsible, inter alia, for the company’s successful capital market positioning and various successful financial and M&A transactions, and led the company to the US technology exchange NASDAQ in 2021. Most importantly, he helped ensure the company’s very dynamic international growth.
Previously, Mr. Spillner worked for more than ten years (2005-2016) at the publicly listed 4SC AG, an innovative biopharmaceutical company, where he held the position as Chief Financial Officer and later additionally as Chief Executive Officer. Prior to that, Mr. Spillner had worked at Bioᴹ AG since 1999, initially as Head of Finance & Controlling. Later on, he gained additional responsibility for significant parts of the Bioᴹ investment business and in 2021 also took over the management of the BioM VC Fund as a partner. In this context, he held interim positions as CFO or CEO in portfolio companies.
Mr. Spillner currently holds supervisory board mandates at Nanobiotix SA, Paris and Leon-Nanodrugs GmbH, Munich.